Advisory Resource Group Purchases 491 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Advisory Resource Group raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 24.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,461 shares of the pharmaceutical company’s stock after buying an additional 491 shares during the period. Advisory Resource Group’s holdings in Vertex Pharmaceuticals were worth $991,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. Czech National Bank boosted its position in Vertex Pharmaceuticals by 6.2% in the fourth quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock worth $22,486,000 after purchasing an additional 3,260 shares during the last quarter. Whalen Wealth Management Inc. bought a new stake in Vertex Pharmaceuticals in the third quarter worth about $662,000. Concord Wealth Partners boosted its stake in Vertex Pharmaceuticals by 32.6% in the fourth quarter. Concord Wealth Partners now owns 3,508 shares of the pharmaceutical company’s stock valued at $1,413,000 after acquiring an additional 862 shares during the last quarter. Mizuho Securities USA LLC grew its position in shares of Vertex Pharmaceuticals by 289.0% during the 3rd quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock valued at $35,994,000 after acquiring an additional 57,497 shares during the period. Finally, Nordea Investment Management AB grew its holdings in Vertex Pharmaceuticals by 19.4% during the fourth quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company’s stock valued at $137,783,000 after purchasing an additional 55,739 shares during the period. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $469.32 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The business’s 50 day simple moving average is $435.87 and its two-hundred day simple moving average is $462.68. The stock has a market capitalization of $120.86 billion, a P/E ratio of -235.84, a price-to-earnings-growth ratio of 1.80 and a beta of 0.41.

Analysts Set New Price Targets

A number of brokerages have recently commented on VRTX. BMO Capital Markets dropped their price target on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a research report on Friday, December 20th. StockNews.com downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 21st. Bank of America lowered their price target on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a research report on Thursday, December 19th. Royal Bank of Canada raised their price objective on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $502.58.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.